Results for
"[search-keyword]"
Sponsor content
59 result(s) found, displaying 1 to 10
- APRETUDE cabotegravir (as sodium) 30 mg film coated tablet bottle (377442)ARTGAustralian Register of Therapeutic Goods (ARTG) information for APRETUDE cabotegravir (as sodium) 30 mg film coated tablet bottle.
- APRETUDE cabotegravir 600 mg/3 mL prolonged-release suspension for injection vial (377474)ARTGAustralian Register of Therapeutic Goods (ARTG) information for APRETUDE cabotegravir 600 mg/3 mL prolonged-release suspension for injection vial.
- AusPAR: ApretudeAustralian Public Assessment Report (AusPAR)AusPAR for Apretude (cabotegravir) for the prevention (to reduce the risk) of sexually acquired HIV-1 infection.
- TRELAVUE dolutegravir (as sodium) 50 mg/abacavir (as sulfate) 600 mg/lamivudine 300 mg tablet bottle Cancelled under Section 30(1)(c) of the ActCancellation by sponsorRequested by ViiV Healthcare Pty Ltd
- TIVICAY PD dolutegravir (as sodium) 5 mg dispersible tablet bottle (340591)ARTGAustralian Register of Therapeutic Goods (ARTG) information for TIVICAY PD dolutegravir (as sodium) 5 mg dispersible tablet bottle.
- APRETUDE (ViiV Healthcare Pty Ltd)Prescription medicine registrationActive ingredients: cabotegravir sodium, cabotegravir.
- AusPAR: Tivicay and Tivicay PDAustralian Public Assessment Report (AusPAR)TIVICAY (dolutegravir ) for treatment of HIV infection in combination with other antiretroviral agents.
- RUKOBIA fostemsavir (as trometamol) 600 mg extended release tablet bottle (337863)ARTGAustralian Register of Therapeutic Goods (ARTG) information for RUKOBIA fostemsavir (as trometamol) 600 mg extended release tablet bottle.
- CABENUVA cabotegravir 600 mg/3 mL plus rilpivirine 900 mg/3 mL prolonged-release suspensions for injection vials (323783)ARTGAustralian Register of Therapeutic Goods (ARTG) information for CABENUVA cabotegravir 600 mg/3 mL plus rilpivirine 900 mg/3 mL prolonged-release suspensions for injection vials.
- CABENUVA cabotegravir 400 mg/2 mL plus rilpivirine 600 mg/2 mL prolonged-release suspensions for injection vials (323784)ARTGAustralian Register of Therapeutic Goods (ARTG) information for CABENUVA cabotegravir 400 mg/2 mL plus rilpivirine 600 mg/2 mL prolonged-release suspensions for injection vials.